Filed in archive
Drugs, Vaccines and Therapeutics
, Genomics, Proteomics and Bioinformatics
, Microbiology
by ruth on January 14, 2008

The Institute is now leading a UK-wide study on a new treatment involving the drug Sirolimus. This was first identified from a soil sample taken from Easter Island and has been shown in the past to control the activity of a protein, mTOR, which is normally controlled by the TSC1 and TSC2 genes. If the genes fail, mTOR is too active leading to tuberous sclerosis.
The UK study tested the effects of Sirolimus on kidney tumours in patients with tuberous sclerosis and a related condition, LAM, a lung and kidney disease affecting young women. The study is at the half-way stage but after one year of treatment the diameters of the tumours have shrunk by an average of 26 per cent. A parallel study in the United States has also reported similar results.
The results of the two studies are published in The New England Journal of Medicine.
Source
Image: Earliest illustration of tuberous sclerosis, from Rayer's atlas of skin diseases, 1835.
Tags:
macrolide
sirolimus
rapamune
genetics
genetic+disease
genetic
tuberous+sclerosis
sirolimus+rapamune
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/110380
Mr Wong
Vote for Sirolimus (Rapamune) May Treat Genetic Disease Tuberous Sclerosis:
|
Rating: 4.00 out of 2 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







